(1S,2S)-Bortezomib |
| Catalog No.GC62193 |
(1S,2S)-보르테조밉은 보르테조밉의 거울상 이성질체입니다. 보르테조밉은 세포 투과성, 가역성, 선택적 프로테아좀 억제제이며 트레오닌 잔기를 표적으로 하여 20S 프로테아좀(Ki 0.6nM)을 강력하게 억제합니다. Bortezomib은 세포주기를 방해하고 세포 사멸을 유도하며 NF-κB를 억제합니다. 보르테조밉은 항암제이자 인간에게 사용되는 최초의 치료적 프로테아좀 억제제이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1132709-14-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3].
[1]. Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55(7):697-705.
[2]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.
[3]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *